Safety evaluation and effect of consumption of combined extract of Ginger and Mulberry to reduce the risk of metabolic disorders

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210616006

Enrollment

Registered

2021-06-16

Start date

2022-05-31

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy conditions Ginger Mulberry metabolic disorders working memory cognitive processing

Interventions

Subjects are received the placebo product which has the same color and smells look like the combined extract of Ginger and Mulberry ,Subjects are received a combined extract of Ginger and Mulberry 500

Placebo Comparator Other,Experimental Dietary Supplement,Experimental Dietary Supplement

Placebo,Combined extract of Ginger and Mulberry 500 mg/day,Combined extract of Ginger and Mulberry 1,000 mg/day

Eligibility

Sex/Gender

All

Age

35 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 35-60 years old 2.Body Mass Index (BMI) between 25-29.99 kg/m2 3.Blood pressure less than 140/90 mm Hg and Fasting Blood Sugar (FBS) after fasts for 8 hours less than 126 mg/dL

Exclusion criteria

Exclusion criteria: 1.Volunteers who have been diagnosed with one of the following; cardiovascular diseases, respiratory diseases, neuropsychological diseases, liver disease (AST more than 64 U/L, ALT more than 50 U/L), Kidney disease (estimate GFR less than 90 ml/min), autoimmune disease, hematological disorder, and cancer 2.Volunteers who require supplements or any drug that affect the nervous system by order of the doctor before trial 3.Volunteers who use supplements or any drug that affect the body weight, glucose, and lipid level before trial 4.Smoking more than 10 pieces/ day 5.Drinking alcohol more than 5 times/ day 6.Volunteers who participate in other projects 7. Pregnancy or lactating women

Design outcomes

Primary

Measure	Time frame
Metabolic parameters include Homeostasis Model Assessment Insulin Resistance (HOMA-IR) index, Atherosclerosis index (AI Index) , Atherogenic index of plasma (AIP), and Oxidized LDL 8 weeks Laboratory	—

Secondary

Measure	Time frame
The changes of hematological and clinical chemistry parameters 8 weeks Laboratory, Acetylcholinesterase and Monoamine oxidase enzyme (MAOA and MAOB) 8 weeks Laboratory,Oxidative stress markers include Malondialdehyde (MDA), Superoxide dismutase (SOD), Catalase (CAT), and Glutathione peroxidase (GSH-Px) 8 weeks Laboratory,Angiotensin converting enzyme (ACE) 8 weeks Elisa method,Advanced glycation end products (AGEs) 8 weeks Elisa method,Homocysteine 8 weeks Laboratory,Inflammatory markers include C-Reactive protein (CRP), IL-1 , and IL-6 8 weeks Elisa method,Body Composition, Body Mass Index (BMI), and Anthropometry 8 weeks Equipment,The changes of electrocardiogram 8 weeks Electrocardiography,Physical fitness 8 weeks Equipment	—

Measure

Time frame

The changes of hematological and clinical chemistry parameters 8 weeks Laboratory, Acetylcholinesterase and Monoamine oxidase enzyme (MAOA and MAOB) 8 weeks Laboratory,Oxidative stress markers include Malondialdehyde (MDA), Superoxide dismutase (SOD), Catalase (CAT), and Glutathione peroxidase (GSH-Px) 8 weeks Laboratory,Angiotensin converting enzyme (ACE) 8 weeks Elisa method,Advanced glycation end products (AGEs) 8 weeks Elisa method,Homocysteine 8 weeks Laboratory,Inflammatory markers include C-Reactive protein (CRP), IL-1 , and IL-6 8 weeks Elisa method,Body Composition, Body Mass Index (BMI), and Anthropometry 8 weeks Equipment,The changes of electrocardiogram 8 weeks Electrocardiography,Physical fitness 8 weeks Equipment

—

Countries

Thailand

Contacts

Public ContactWipawee Thukhammee

Khon Kaen University

wipath@kku.ac.th0850016805

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026